Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
about
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.Dendritic cell immunotherapy in uterine cancer.A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.Effect of ex vivo culture duration on phenotype and cytokine production by mature dendritic cells derived from peripheral blood monocytesIsolation and generation of human dendritic cells.Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugsAntigen-specific cellular immunotherapy of leukemia.Intranasal delivery of vaccines against HIV.Langerhans-type and monocyte-derived human dendritic cells have different susceptibilities to mRNA electroporation with distinct effects on maturation and activation: implications for immunogenicity in dendritic cell-based immunotherapy.Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In VivoDendritic cell-based immunotherapy in ovarian cancer.In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes.mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.Potential therapeutic applications of RNA cap analogs.Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.mRNA-based dendritic cell vaccines.Modification of human embryonic stem cell-derived dendritic cells with mRNA for efficient antigen presentation and enhanced potency.Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.A suppressor of cytokine signaling 1 antagonist enhances antigen-presenting capacity and tumor cell antigen-specific cytotoxic T lymphocyte responses by human monocyte-derived dendritic cells.Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA.Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells.Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase.The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses.Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells.The impact of electrical charge on the viability and physiology of dendritic cells.Efficient gene transfer in CLL by mRNA electroporation.CD8(+) T-cell priming and boosting: more antigen-presenting DC, or more antigen per DC?mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L, and CD70).
P2860
Q34201274-C32A483F-1101-4E5C-B286-CF64B208044AQ34291122-3241201E-9567-49FE-B8D3-8D0A9FFA9E3AQ34382930-164D378B-865F-4452-9A6B-CC626E7BA8DBQ34658123-ED2345EA-7FEF-4908-99E3-DD6B218B45DBQ36025111-CD8C82C5-A307-46B1-AD48-520A48F90FA7Q36154837-5ABEDEAE-94D6-4E38-A732-F796D276F950Q36240201-4D6ADF89-727B-4D41-9959-362F35720819Q36409054-F408EE03-E929-4C49-87EB-6812FB01E7C6Q37008819-D041E908-01C3-4927-A082-B36AD808BF4EQ37467831-53AE75B2-A895-479D-954C-0ECCB40A3310Q37554417-22DBBDD1-CD9E-42D6-A322-D3172F8A8CA1Q37591900-9B183058-85C4-4159-9A1A-C7FA10740F06Q38071900-2725026B-29AD-4324-96D2-B55151B54E43Q38116576-022B3E55-7716-4924-945C-668945857FAFQ38208388-9CB2921D-DF8E-42E8-BC1A-028C4D9B8677Q38246769-B71F96AC-A5BB-488A-A421-F0E8B6E9E6B6Q39547016-0006D7D8-C3EA-4459-9C0F-D5D4933663EAQ40346494-032EEF17-8C3C-4F5F-AA69-6E6883F81707Q41867724-A847C701-7F10-4914-A2C5-63FF0F53C9DFQ42536013-61F0A7CE-3651-4DF5-BCF5-D9D855301E17Q42751318-1292EC7F-A9A3-42F5-89EA-973E3BEDEEB8Q43097170-548A6A70-12F3-4F15-B59E-587B5FA8F605Q43279090-2BC48B2A-BB71-4F5F-8AF3-B47DEEF558C8Q44436557-25391937-D99B-4A0B-BD12-69C5C47764E0Q45858586-68BAEC3B-C208-45AB-AF0E-3E84D3F86216Q45863132-41B05C6D-0A15-40F7-866A-4C694387EE7BQ46777207-7ECF80EE-D20B-4A0D-B316-34BDB2A9C0F7Q49039662-F173D28F-CDF1-42D6-B628-E15B8CC93A6CQ50471175-D48BE862-3B0C-45AC-BD2A-EC351EAB09ACQ53092559-F0361F00-E32B-4DEB-B338-65230B198C64
P2860
Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Electroporation of immature an ...... dendritic cell-based vaccines.
@en
Electroporation of immature an ...... dendritic cell-based vaccines.
@nl
type
label
Electroporation of immature an ...... dendritic cell-based vaccines.
@en
Electroporation of immature an ...... dendritic cell-based vaccines.
@nl
prefLabel
Electroporation of immature an ...... dendritic cell-based vaccines.
@en
Electroporation of immature an ...... dendritic cell-based vaccines.
@nl
P2093
P2860
P356
P1433
P1476
Electroporation of immature an ...... dendritic cell-based vaccines.
@en
P2093
Bonehill A
Brasseur F
Corthals J
Dullaers M
Michiels A
Thielemans K
Tuyaerts S
Van Meirvenne S
P2860
P2888
P304
P356
10.1038/SJ.GT.3302471
P577
2005-05-01T00:00:00Z
P5875
P6179
1040284064